Content about Angioedema

December 27, 2013

Drug maker Shire is extending the deadline for its offer to buy Exton, Pa.-based ViroPharma for $4.2 billion, Shire said Friday.

DUBLIN — Drug maker Shire is extending the deadline for its offer to buy Exton, Pa.-based ViroPharma for $4.2 billion, Shire said Friday.

The company said it had extended the expiration date of its tender offer for ViroPharma until Jan. 9. The offer had previously been planned to expire on Thursday. Shire announced the $50-per-share offer last month.

December 12, 2012

Drug maker ViroPharma has launched an education campaign focused on a rare, debilitating and life-threatening genetic disorder.

EXTON, Pa. — Drug maker ViroPharma has launched an education campaign focused on a rare, debilitating and life-threatening genetic disorder.

The company announced Wednesday the launch of the unbranded campaign focused on hereditary angioedema, particularly the emotional and psychological burden faced by patients with the disease, which results from deficiency of the human plasma protein C1 inhibitor and causes attacks of swelling and pain.

April 26, 2012

Patients with a rare, life-threatening genetic immune system disorder can receive treatment for sudden episodes more quickly and cost-effectively at home than if they go to the emergency room, according to a Walgreens Infusion Services study being presented Wednesday at the National Home Infusion Association Annual Conference and Exposition here.

PHOENIX — Patients with a rare, life-threatening genetic immune system disorder can receive treatment for sudden episodes more quickly and cost-effectively at home than if they go to the emergency room, according to a Walgreens Infusion Services study being presented Wednesday at the National Home Infusion Association Annual Conference and Exposition here.

August 26, 2011

The Food and Drug Administration has approved a drug made by Shire for a rare autoimmune condition, the agency said.

SILVER SPRING, Md. — The Food and Drug Administration has approved a drug made by Shire for a rare autoimmune condition, the agency said.

The FDA announced the approval of Firazyr (icatibant) for acute attacks of hereditary angioedema in patients ages 18 years and older. HAE, which affects fewer than 30,000 people in the United States, results from improper function of C1 inhibitor, a protein that regulates how certain immune system and blood clotting pathways function.

February 28, 2011

British drug maker Shire again is trying to win approval for a hereditary angioedema drug that the Food and Drug Administration had previously declined to approve.

DUBLIN — British drug maker Shire again is trying to win approval for a hereditary angioedema drug that the Food and Drug Administration had previously declined to approve.

Shire said Monday that it had submitted a response to the "not approvable letter" the FDA sent to German subsidiary Jerini AG in April 2008 for the drug Firazyr (icatibant).